Table 1.

Clinical descriptors for all patients with SLE at study visit (n=92)

	Overall	VWF:Ag (Rs coefficient or median level)	VWF:RCo (Rs coefficient or median level)	VWF RCo/Ag ratio (Rs coefficient or median level)
Age (years)	49.9 (36–60)	0.17	0.146	−0.15
Female gender	81 (88%)	141/153	120/112	0.8
Disease duration (months)	126 (61–213)	0.13	0.06	−0.13
SLEDAI-2K	6 (2–12)	0.18	−0.06	0.18
SLICC-DI	1 (0–2)	0.11	−0.04	−0.25*
Prednisone dose (mg/d)	5 (0–7.5)	0.07	0.18	−0.01
BMI	25 (22–28)	0.25*	0.13	−0.1
Diastolic blood pressure	80 (68.5–85)	0.12	0.06	−0.15
Renal disease	45 (49%)	133/143	116/126	0.82
Vasculitis	27 (29%)	147/142	140/120	0.82
Serositis	21 (23%)	164/142*	140/120	0.83
MI, stroke or thrombosis	24 (26%)	153/141	120/120	0.83
aPL antibody presence	37 (40%)	141/142	120/126	0.81
Hydroxychloroquine user	56 (61%)	139/149	120/140	0.84
Immunosuppressant user	32 (35%)	138/140	120/126	0.82
Aspirin/warfarin user	31/8 (34%/9%)	140/140	120/123	0.82
Fish oil, regular user	39 (43%)	158/142	140/120	0.83

Overall figures represent absolute numbers (%) or median values (IQR) for the whole cohort. The association of each disease manifestation with VWF:Ag levels, VWF:RCo and VWF RCo/Ag ratio is given as Rs for continuous variables or as median levels for dichotomous variables.

*Statistically significant correlation observed in all patients or a significant difference in level compared with other patients not experiencing that disease manifestation (p<0.05).

Ag, antigen; aPL, antiphospholipid; BMI, body mass index; MI, myocardial infarction; RCo, ristocetin cofactor; Rs, Spearman rank correlation coefficients; SLEDAI-2K, Systemic Lupus Erythematous Disease Activity Index 2000; SLICC-DI, Systemic Lupus International Collaborative Clinics Damage Index; SLE, systemic lupus erythematous; VWF, von Willebrand factor.